Abstract 341P
Background
The three most famous NUP214-associated gene rearrangements found in leukemia patients are SET::NUP214, NUP214::ABL1, and DEK::NUP214. Regardless of the NUP214’s partner gene or disease type, one common feature NUP214 rearrangements have in common is their association with resistance to treatment and poor prognosis. However, numerous mouse model experiments have shown that NUP214 rearrangement alone is insufficient for, or at least inefficient at, leukemogenesis. Therefore, identification of concurrent mutations as well as sensitive detection of these fusion genes are important for accurate assessment and tailored management of leukemia patients.
Methods
To identify patients with NUP214 gene rearrangement, RNA sequencing results of diagnostic bone marrow aspirates were retrospectively reviewed. Concurrent targeted next generation sequencing results as well as the patients’ demographics, karyotype, and flow cytometry information were also reviewed.
Results
A total of ten patients harboring NUP214 gene rearrangement were identified, among which four had SET: NUP214, three had DEK: NUP214, and three had NUP214: ABL1. Their diagnosis varied depending on the fusion type. Concurrent gene mutations were found in all ten cases. PFH6 mutations was the most common (5/10) followed by WT1 (3/10), NOTCH1 (3/10), FLT3-ITD (3/10) NRAS (2/10), and EZH2 (2/10). One of these patients was the world’s second case of NUP214: ABL1-positive AML.
Conclusions
We have shown the patient characteristics and concurrent test results of ten NUP214-rearranged leukemia patients. Since these gene rearrangements can serve as potential minimal residual disease markers as well as therapeutic targets, we hope our elucidation of the context in which they were discovered will help future research in regard to tailored monitoring and treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract